Repligen (NASDAQ:RGEN) Releases FY 2021 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.210-2.280 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.910. The company issued revenue guidance of $565 million-$590 million, compared to the consensus revenue estimate of $513.38 million.

Several brokerages have recently issued reports on RGEN. HC Wainwright raised their price objective on Repligen from $225.00 to $240.00 and gave the stock a buy rating in a research note on Tuesday. Craig Hallum increased their price target on Repligen from $245.00 to $251.00 and gave the stock a buy rating in a research report on Thursday, February 25th. Finally, SVB Leerink boosted their price objective on Repligen from $220.00 to $250.00 and gave the company an outperform rating in a report on Wednesday, March 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Repligen currently has a consensus rating of Buy and an average price target of $218.20.

Shares of Repligen stock traded down $3.78 on Wednesday, hitting $171.68. The company’s stock had a trading volume of 8,108 shares, compared to its average volume of 391,495. The company has a market capitalization of $9.43 billion, a price-to-earnings ratio of 209.39, a price-to-earnings-growth ratio of 4.18 and a beta of 0.94. Repligen has a 1 year low of $109.38 and a 1 year high of $228.84. The company has a debt-to-equity ratio of 0.21, a quick ratio of 12.13 and a current ratio of 13.67. The firm has a fifty day moving average price of $202.69 and a 200-day moving average price of $199.46.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.26. The business had revenue of $142.80 million during the quarter, compared to analysts’ expectations of $117.88 million. Repligen had a return on equity of 6.58% and a net margin of 13.40%. The business’s revenue was up 87.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 earnings per share. As a group, analysts forecast that Repligen will post 1.44 EPS for the current year.

In other Repligen news, SVP James Bylund sold 360 shares of Repligen stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $204.25, for a total value of $73,530.00. Following the transaction, the senior vice president now directly owns 6,324 shares in the company, valued at $1,291,677. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 21,900 shares of the company’s stock in a transaction dated Thursday, March 4th. The shares were sold at an average price of $190.19, for a total transaction of $4,165,161.00. Following the completion of the sale, the chief executive officer now directly owns 242,970 shares of the company’s stock, valued at $46,210,464.30. The disclosure for this sale can be found here. Insiders have sold 47,382 shares of company stock worth $9,056,388 over the last 90 days. Insiders own 1.70% of the company’s stock.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Story: How is the discount rate different from the Federal Funds rate?

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.